Michał Oleszko, Lech Zaręba, Aleksandra Łoś, Nikola Król, Hanna Czajka
{"title":"Herpes zoster epidemiology during and after the COVID-19 pandemic: A 5-year retrospective study from primary care in Poland.","authors":"Michał Oleszko, Lech Zaręba, Aleksandra Łoś, Nikola Król, Hanna Czajka","doi":"10.17219/acem/222571","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Herpes zoster (HZ) is caused by reactivation of latent varicella-zoster virus and affects 25-30% of individuals, with the highest incidence in adults aged ≥50 years and a lifetime risk exceeding 50% after the age of 85. Its most common complication is postherpetic neuralgia (PHN), i.e., persistent neuropathic pain. Reports of increased HZ incidence during or after SARS-CoV-2 infection suggest potential epidemiological associations requiring further investigation.</p><p><strong>Objectives: </strong>Our goals were to evaluate the incidence of HZ and its complications during the pandemic and the post-pandemic period in primary care settings in Poland.</p><p><strong>Material and methods: </strong>We conducted a retrospective multicenter study in 20 primary care clinics in Poland, covering 43,949-81,091 patients from 2020 to 2024. Incident HZ cases and complications (PHN, herpes zoster ophthalmicus (HZO), HZ oticus, and disseminated HZ) were identified, and demographic data, including place of residence, were collected. Statistical analyses included χ2 or Fisher's exact tests, Student's t-tests or nonparametric equivalents, odds ratios (ORs) with 95% confidence intervals (95% CIs), and receiver operating characteristic (ROC) analysis to assess age-related risk of prolonged symptoms.</p><p><strong>Results: </strong>A total of 570 HZ cases were recorded from 2020 to 2024. Incidence ranged from 1.61 to 2.14 per 1,000 persons and increased with age, reaching 6.57 per 1,000 in individuals aged ≥80 years. Patients aged ≥71 years had higher odds of developing PHN (pain persisting for >90 days) than younger patients (OR = 4.47; 95% CI: 2.30-8.67; p < 0.001). Older adults were also more likely to develop HZO (p = 0.001). Rural incidence was significantly lower during the pandemic than in the post-pandemic period (p = 0.005), with no significant differences in urban or semi-urban areas.</p><p><strong>Conclusions: </strong>The risk of HZ, PHN, and HZO rises with age. During the pandemic (2020-2021), rural incidence was significantly lower than in the post-pandemic period (2022-2024). The study provides updated data on HZ epidemiology in Poland and highlights the impact of the COVID-19 pandemic on healthcare access and HZ reporting in rural areas.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17219/acem/222571","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Herpes zoster (HZ) is caused by reactivation of latent varicella-zoster virus and affects 25-30% of individuals, with the highest incidence in adults aged ≥50 years and a lifetime risk exceeding 50% after the age of 85. Its most common complication is postherpetic neuralgia (PHN), i.e., persistent neuropathic pain. Reports of increased HZ incidence during or after SARS-CoV-2 infection suggest potential epidemiological associations requiring further investigation.
Objectives: Our goals were to evaluate the incidence of HZ and its complications during the pandemic and the post-pandemic period in primary care settings in Poland.
Material and methods: We conducted a retrospective multicenter study in 20 primary care clinics in Poland, covering 43,949-81,091 patients from 2020 to 2024. Incident HZ cases and complications (PHN, herpes zoster ophthalmicus (HZO), HZ oticus, and disseminated HZ) were identified, and demographic data, including place of residence, were collected. Statistical analyses included χ2 or Fisher's exact tests, Student's t-tests or nonparametric equivalents, odds ratios (ORs) with 95% confidence intervals (95% CIs), and receiver operating characteristic (ROC) analysis to assess age-related risk of prolonged symptoms.
Results: A total of 570 HZ cases were recorded from 2020 to 2024. Incidence ranged from 1.61 to 2.14 per 1,000 persons and increased with age, reaching 6.57 per 1,000 in individuals aged ≥80 years. Patients aged ≥71 years had higher odds of developing PHN (pain persisting for >90 days) than younger patients (OR = 4.47; 95% CI: 2.30-8.67; p < 0.001). Older adults were also more likely to develop HZO (p = 0.001). Rural incidence was significantly lower during the pandemic than in the post-pandemic period (p = 0.005), with no significant differences in urban or semi-urban areas.
Conclusions: The risk of HZ, PHN, and HZO rises with age. During the pandemic (2020-2021), rural incidence was significantly lower than in the post-pandemic period (2022-2024). The study provides updated data on HZ epidemiology in Poland and highlights the impact of the COVID-19 pandemic on healthcare access and HZ reporting in rural areas.
期刊介绍:
Advances in Clinical and Experimental Medicine has been published by the Wroclaw Medical University since 1992. Establishing the medical journal was the idea of Prof. Bogumił Halawa, Chair of the Department of Cardiology, and was fully supported by the Rector of Wroclaw Medical University, Prof. Zbigniew Knapik. Prof. Halawa was also the first editor-in-chief, between 1992-1997. The journal, then entitled "Postępy Medycyny Klinicznej i Doświadczalnej", appeared quarterly.
Prof. Leszek Paradowski was editor-in-chief from 1997-1999. In 1998 he initiated alterations in the profile and cover design of the journal which were accepted by the Editorial Board. The title was changed to Advances in Clinical and Experimental Medicine. Articles in English were welcomed. A number of outstanding representatives of medical science from Poland and abroad were invited to participate in the newly established International Editorial Staff.
Prof. Antonina Harłozińska-Szmyrka was editor-in-chief in years 2000-2005, in years 2006-2007 once again prof. Leszek Paradowski and prof. Maria Podolak-Dawidziak was editor-in-chief in years 2008-2016. Since 2017 the editor-in chief is prof. Maciej Bagłaj.
Since July 2005, original papers have been published only in English. Case reports are no longer accepted. The manuscripts are reviewed by two independent reviewers and a statistical reviewer, and English texts are proofread by a native speaker.
The journal has been indexed in several databases: Scopus, Ulrich’sTM International Periodicals Directory, Index Copernicus and since 2007 in Thomson Reuters databases: Science Citation Index Expanded i Journal Citation Reports/Science Edition.
In 2010 the journal obtained Impact Factor which is now 1.179 pts. Articles published in the journal are worth 15 points among Polish journals according to the Polish Committee for Scientific Research and 169.43 points according to the Index Copernicus.
Since November 7, 2012, Advances in Clinical and Experimental Medicine has been indexed and included in National Library of Medicine’s MEDLINE database. English abstracts printed in the journal are included and searchable using PubMed http://www.ncbi.nlm.nih.gov/pubmed.